Catalyst Pharmaceuticals (CPRX) Operating Expenses (2010 - 2026)

Catalyst Pharmaceuticals' Operating Expenses history runs 17 years deep, the most recent figure standing at $76.2 million for Q1 2026.

• Quarterly Operating Expenses fell 2.43% year-over-year to $76.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $329.3 million (up 8.58% YoY) and the FY2025 annual result came in at $331.2 million, up 11.67% from the prior year.
• Operating Expenses was $76.2 million for Q1 2026 at Catalyst Pharmaceuticals, down from $90.8 million in the prior quarter.
• Across five years, Operating Expenses topped out at $139.9 million in Q3 2023 and bottomed at $24.5 million in Q2 2022.
• A 5-year average of $66.3 million and a median of $71.4 million in 2024 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2023 — Operating Expenses surged 335.18% — and 2024, when it sank 44.39%.
• Catalyst Pharmaceuticals' Operating Expenses stood at $30.0 million in 2022, then jumped by 129.92% to $68.9 million in 2023, then increased by 14.67% to $79.0 million in 2024, then climbed by 14.93% to $90.8 million in 2025, then slipped by 16.1% to $76.2 million in 2026.
• Business Quant data shows CPRX's Operating Expenses at $76.2 million in Q1 2026, $90.8 million in Q4 2025, and $82.1 million in Q3 2025.